These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23943401)

  • 21. Evaluation of food effect on the oral absorption of clarithromycin from immediate release tablet using physiological modelling.
    Radwan A; Jayyousi R; Shraim N; Zaid AN
    Biopharm Drug Dispos; 2019 Apr; 40(3-4):121-134. PubMed ID: 30891805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers.
    Lake OA; Olling M; Barends DM
    Eur J Pharm Biopharm; 1999 Jul; 48(1):13-9. PubMed ID: 10477323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
    Wei H; Löbenberg R
    Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiologically Based Biopharmaceutics Model of Vildagliptin Modified Release (MR) Tablets to Predict In Vivo Performance and Establish Clinically Relevant Dissolution Specifications.
    Madny MA; Deshpande P; Tumuluri V; Borde P; Sangana R
    AAPS PharmSciTech; 2022 Apr; 23(4):108. PubMed ID: 35386066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel bicephalous heterolipid based self-microemulsifying drug delivery system for solubility and bioavailability enhancement of efavirenz.
    Chaudhari KS; Akamanchi KG
    Int J Pharm; 2019 Apr; 560():205-218. PubMed ID: 30742985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro dissolution method fitted to in vivo absorption profile of rivaroxaban immediate-release tablets applying in silico data.
    Wingert NR; Dos Santos NO; Campanharo SC; Simon ES; Volpato NM; Steppe M
    Drug Dev Ind Pharm; 2018 May; 44(5):723-728. PubMed ID: 29192518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigating a Modified Apparatus to Discriminate the Dissolution Capacity In Vitro and Establish an IVIVC of Mycophenolate Mofetil Tablets in the Fed State.
    Zhang G; Sun M; Jiang S; Wang L; Tan Y; Wang L; Cheng Z
    J Pharm Sci; 2021 Mar; 110(3):1240-1247. PubMed ID: 33096138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IVIVC for fenofibrate immediate release tablets using solubility and permeability as in vitro predictors for pharmacokinetics.
    Buch P; Holm P; Thomassen JQ; Scherer D; Branscheid R; Kolb U; Langguth P
    J Pharm Sci; 2010 Oct; 99(10):4427-36. PubMed ID: 20737642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
    Patel GV; Patel VB; Pathak A; Rajput SJ
    Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC.
    Ruiz Picazo A; Martinez-Martinez MT; Colón-Useche S; Iriarte R; Sánchez-Dengra B; González-Álvarez M; García-Arieta A; González-Álvarez I; Bermejo M
    Mol Pharm; 2018 Jun; 15(6):2307-2315. PubMed ID: 29746133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioequivalence Comparison of Pediatric Dasatinib Formulations and Elucidation of Absorption Mechanisms Through Integrated PBPK Modeling.
    Vaidhyanathan S; Wang X; Crison J; Varia S; Gao JZH; Saxena A; Good D
    J Pharm Sci; 2019 Jan; 108(1):741-749. PubMed ID: 30439460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterising Drug Release from Immediate-Release Formulations of a Poorly Soluble Compound, Basmisanil, Through Absorption Modelling and Dissolution Testing.
    Stillhart C; Parrott NJ; Lindenberg M; Chalus P; Bentley D; Szepes A
    AAPS J; 2017 May; 19(3):827-836. PubMed ID: 28236228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developing Quantitative In Vitro-In Vivo Correlation for Fenofibrate Immediate-Release Formulations With the Biphasic Dissolution-Partition Test Method.
    Xu H; Shi Y; Vela S; Marroum P; Gao P
    J Pharm Sci; 2018 Jan; 107(1):476-487. PubMed ID: 28666964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation.
    Mittapalli RK; Nuthalapati S; Delke DeBord AE; Xiong H
    Pharm Res; 2017 Jun; 34(6):1187-1192. PubMed ID: 28243955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
    Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo in silico pharmacokinetic simulation studies of carvedilol-loaded nanocapsules using GastroPlus.
    George JK; Singh SK; Verma PR
    Ther Deliv; 2016; 7(5):305-18. PubMed ID: 27075951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and validation of a Level A in-vitro in-vivo correlation for tofacitinib modified-release tablets using extrudable core system osmotic delivery technology.
    Kushner J; Lamba M; Stock T; Wang R; Nemeth MA; Alvey C; Chen R; DeMatteo V; Blanchard A
    Eur J Pharm Sci; 2020 Apr; 147():105200. PubMed ID: 31863865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz).
    Gao JZh; Hussain MA; Motheram R; Gray DA; Benedek IH; Fiske WD; Doll WJ; Sandefer E; Page RC; Digenis GA
    J Pharm Sci; 2007 Nov; 96(11):2970-7. PubMed ID: 17542016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.
    Tsume Y; Langguth P; Garcia-Arieta A; Amidon GL
    Biopharm Drug Dispos; 2012 Oct; 33(7):366-77. PubMed ID: 22815122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.